GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Total Assets

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Total Assets : $418.8 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Total Assets?

Arcturus Therapeutics Holdings's Total Assets for the quarter that ended in Mar. 2024 was $418.8 Mil.

Warning Sign:

If a company builds assets at 77.7% a year, faster than its revenue growth rate of 37.3% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Arcturus Therapeutics Holdings's average Total Assets Growth Rate was -8.70% per year. During the past 3 years, the average Total Assets Growth Rate was 116.40% per year. During the past 5 years, the average Total Assets Growth Rate was 77.70% per year. During the past 10 years, the average Total Assets Growth Rate was 62.70% per year.

During the past 13 years, Arcturus Therapeutics Holdings's highest 3-Year average Total Assets Growth Rate was 486.70%. The lowest was -29.10%. And the median was 66.75%.

Total Assets is connected with ROA %. Arcturus Therapeutics Holdings's annualized ROA % for the quarter that ended in Mar. 2024 was -25.29%. Total Assets is also linked to Revenue through Asset Turnover. Arcturus Therapeutics Holdings's Asset Turnover for the quarter that ended in Mar. 2024 was 0.08.


Arcturus Therapeutics Holdings Total Assets Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Total Assets Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.14 476.46 392.81 450.39 429.40

Arcturus Therapeutics Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 470.86 430.65 457.65 429.40 418.85

Arcturus Therapeutics Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Arcturus Therapeutics Holdings's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=278.513+150.889
=429.4

Arcturus Therapeutics Holdings's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=263.972+154.877
=418.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arcturus Therapeutics Holdings  (NAS:ARCT) Total Assets Explanation

Total Assets is connected with ROA %.

Arcturus Therapeutics Holdings's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-107.268/( (429.402+418.849)/ 2 )
=-107.268/424.1255
=-25.29 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Arcturus Therapeutics Holdings's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=32.598/( (429.402+418.849)/ 2 )
=32.598/424.1255
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Arcturus Therapeutics Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Executives
Pad Chivukula officer: Chief Scientific Officer & COO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld officer: See Remarks 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne director, 10 percent owner, officer: President and CEO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc. director, 10 percent owner 60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata officer: Chief Legal Officer 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine officer: Chief Financial Officer 82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes officer: Chief Development Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow director 2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes director C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Headlines

From GuruFocus

Arcturus Therapeutics to Attend the Following Investor Conferences

By Business Wire Business Wire 09-01-2022

Arcturus Therapeutics to Attend Upcoming Investor Conferences

By Business Wire Business Wire 02-06-2023